Introduction
============

Behçet's disease (BD) is a chronic multisystem inflammatory disorder characterized by mucocutaneous, ocular, vascular, and central nervous system manifestations. The common manifestations are recurrent oral and genital ulcers and ocular involvement. Venous or arterial thromboses occur in 7% to 38% of patients \[[@r1]\]. Venous thrombosis is more common than arterial thrombosis, with relative frequencies of 90% and 10%, respectively \[[@r2],[@r3]\]. Although vascular lesions are not included in the major diagnostic criteria of BD, one-quarter to one half of patients are likely to develop this complication \[[@r4]-[@r6]\]. Venous thrombosis is a major vascular involvement reported in 7% to 33% of patients with BD \[[@r6]\]. BD has a worldwide distribution but is most common in Japan, the Middle East, and Mediterranean countries. The prevalence of BD in Turkey is particularly high, at 80--420 per 100,000 individuals \[[@r7],[@r8]\]. BD occurs more commonly in men than in women and primarily affects individuals between the second and fourth decades of their life, with a more aggressive course in young male adults. BD is characterized by infiltration of lymphocytes and neutrophils into the affected organs. Cytokines play critical roles in the pathogenesis of BD \[[@r9],[@r10]\]. Several cytokine genes may play crucial roles in host susceptibility to BD, because cytokine production capacity varies among individuals and depends on the cytokine gene polymorphisms \[[@r11]\]. Cytokines are signaling molecules that contribute to inflammatory response and protect the body from pathogens and other environmental factors. Interleukin-4 (IL-4) is a key cytokine that induces the activation and differentiation of B cells and is involved in the development of the T helper-2 subset of lymphocytes. IL-4 has cytotoxic, antitumor effects, inhibits induction of nitric oxide synthase, inhibits release of superoxide by macrophages, and has numerous anti-inflammatory effects \[[@r12]-[@r14]\]. IL-4 also plays a role in the function of macrophages, B-cell and T-cell chemotaxis, the formation of endothelial cell adhesion molecules, and hematopoiesis. Based on these findings, we hypothesized that the genotype of IL-4 in patients with BD may be a determining factor in BD pathogenesis.

Methods
=======

Study population
----------------

The present study included 238 patients with BD and 250 controls, recruited from the Gazi Osmanpaşa University Department of Physical Medicine and Rehabilitation (Tokat, Turkey). The ethics committee of Gazi Osmanpaşa University Medical Faculty approved informed consent in accordance with the study protocol. Patients with BD fulfilled the International Criteria of Behçet's Disease for classification \[[@r15]\]. All patients signed a written consent form after being informed about the details of the study. A complete clinical evaluation was performed for all patients. The controls were selected by excluding a diagnosis of BD. All the individuals in the control group were healthy. The data collection sheet included information such as age, disease duration, deep venous thrombosis, and several clinical characteristics. Individual features of patients with BD and controls are summarized in [Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}. Genotype determination DNA was extracted from 2 ml venous blood according to the kit procedure (Sigma-Aldrich,Taufkirchen, Germany) and stored at −20 °C. To detect 70 bp VNTR polymorphism in the third intron of the IL-4 gene, PCR assay was used as described by Mout et al. \[[@r16]\]. PCR was performed with a 25 μl reaction mixture containing 50 ng DNA, 20 pM of each primer, 200 mM of deoxynucleotide triphosphate (dNTP), 2.5 mM MgCl~2~, 0.5 U Taq polymerase, 10 mM KCl buffer (Fermentas, Shenzhen, China). Amplification was carried out using primers F5' AGG CTG AAA GGG GGA AAG C-3', R5'-CTG TTC ACC TCA ACT GCT CC-3', with initial denaturation at 95 ºC for 5 min, 30 cycles of denaturation at 94 ºC for 30 s, annealing at 58 ºC for 45 s, extension at 72 ºC for 1 min, and final extension at 72 ºC for 10 min. P~1~P~1~ genotype was homozygous wild type, P~1~P~2~ genotype heterozygous mutant, P~2~P~2~ genotype homozygous mutation type, wild type allele was P~1~ and mutant type allele was P~2~, respectively. The PCR products were visualized on three percent agarose gel stained with ethidium bromide. PCR product was of 183 bp for P~1~ allele and 253 bp for P~2~ allele. In order to validate the accuracy and reproducibility of this method, each PCR reaction included negative and positive controls. The second PCR was performed to confirm samples whose results were not clear. Also, to confirm the accuracy of the genotyping, repeated analysis was performed on randomly selected samples. No discrepancies were found.

###### Demographic variables and baseline characteristics of the patients.

  **Individual characteristics**   **Mean±SD**   **Min-Max**
  -------------------------------- ------------- -------------
  Average age of patients          36.36±9.62    20--70
  Average age of controls          35.84±11.36   18--65
  Disease duration, years          6.87±5.96     1--29

###### Clinical findings of BD patients

  **Clinical characteristics**   **Number of Patients (%)**
  ------------------------------ ----------------------------
  Skin lesions                   234(98.3)
  Oral ulcers                    234(98.3)
  Genital ulcers                 168(70.6)
  Ocular inflammation            180(75.6)
  Deep venous thrombosis         71(29.8)
  Colchicine use                 234(98.3)
  Response to colchicine         238(100)
  Papulopustule                  96(40.3)
  Erythema nodosum               63(26.5)

Min-Max: Minimum-maximum values.

Statistical analysis
--------------------

Analysis of the data was performed using SPSS 15.0 (SPSS, Chicago, IL) and the OpenEpi Info software package program \[[@r17]\]. Continuous data were given as mean±SD (standard deviation) and (minimum-maximum values). The frequencies of the alleles and genotypes in the patients and the controls were compared with χ^2^ analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A p value smaller than 0.05 (two-tailed) was statistically significant.

Results
=======

The demographic variables and baseline characteristics of the patients are shown in [Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}. The mean±SD age was 36.36±9.62 in the patient group and 35.84±11.36 in the control group, respectively. There were 114 (47.90%) women and 123 (52.10%) men in the patient group; in the control group, these figures were 155 (62%) and 95 (38%), respectively. [Table 3](#t3){ref-type="table"} presents the distribution of IL-4 70 bp VNTR polymorphic genotypes in the patient group and the control group. Our results showed that there was a statistically significant difference between the groups regarding IL-4 genotype distribution (p\<0.001) and allele frequencies (p\<0.001; [Table 3](#t3){ref-type="table"}). In the present study, the P~2~ allele was a 2.3-fold risk factor for BD (OR, 95% CI; 2.381 \[1.586--3.617\]). When we examined the IL-4 genotype frequencies according to the clinical characteristics, we found a statistically significant association between the P~2~P~2~ genotype and deep venous thrombosis according to the genotype frequencies (p=0.01; [Table 4](#t4){ref-type="table"}). There was also a statistically significant association between the P~2~ allele and deep venous thrombosis according to the allele frequencies (p=0.008; [Table 5](#t5){ref-type="table"}). We examined the ocular involvement distribution according to deep venous thrombosis and found a statistically significant association between ocular involvement and deep venous thrombosis (p=0.014; [Table 6](#t6){ref-type="table"}). In addition, we examined the IL-4 gene 70 bp VNTR genotype and allele frequencies according to clinical status and found that cases with ocular involvement (+) and deep venous thrombosis (+) were associated with the P~2~ allele (p\<0.01; [Table 7](#t7){ref-type="table"}). The IL-4 gene P~1~ allele frequency was 16% in the patient group and 7% in the control group. P~2~ allele occurrence was 84% in the patient group and 93% in the control group ([Table 3](#t3){ref-type="table"}). The frequencies of the P~1~P~1~, P~1~P~2~, and P~2~P~2~ genotypes of the intron 3 VNTR polymorphism in the patient group were 3.4%, 26.1%, and 70.5%, respectively, and 1.2%, 12.8%, and 86.0%, respectively, in the control group. The homozygote P~1~P~1~ genotype frequency of the IL-4 gene was 3.4% in the patient group and 1.2% in the control group. The heterozygote P~1~P~2~ genotype frequency was 26.10% in the patient group and 12.8% in the control group. The homozygote P~2~P~2~ genotype frequency was 70.50% in the patient group and 86% in the control group.

###### Distribution of *IL-4* gene 70 bp VNTR polymorphism and allele frequencies between BD patients and controls.

  **Genotype**                     **Patients** **(n=238; %)**   **Controls** **(n=250; %)**   **χ2**   P value        OR (95%CI)
  -------------------------------- ----------------------------- ----------------------------- -------- -------------- ----------------------
  P~1~P~1~                         8 (3.40)                      3 (1.2)                       17.33    **p\<0.001**   
  P~1~P~2~                         62 (26.10)                    32 (12.8)                                             
  P~2~P~2~                         168 (70.50)                   215 (86)                                              
  P~1~P~1~+ P~1~P~2~: P~2~P~2~     70:168                        35:215                        17.15    **p\<0.001**   2.555 (1.629--4.052)
  I P~1~P~2~+ P~2~P~2~: P~1~P~1~   230:8                         247:3                         2.585    p=0.107        0.349 (0.074--1.295)
  **Allele frequency**                                                                                                 
  P~1~                             78 (16)                       38 (7)                        17.98    **p\<0.001**   2.381 (1.586--3.617)
  P~2~                             398 (84)                      462 (93)                                              

The results that are statistically significant are typed in bold. (Homozygous wild type (P~1~P~1~) heterozygous mutant type (P~1~P~2~) homozygous mutation type (P~2~P~2~), Wild type allele (P~1~) mutant type allele (P~2~).

###### *IL-4* genotype frequencies according to the clinical characteristics in BD patients (n=238).

  **Clinical**             ***Il-4 genotypes***                                          
  ------------------------ ---------------------- ------------ ------------ ------------ ------------
  Oral ulcers              yes                    9(3.81)      45(19.06)    182(77.11)   p\>0.05
  no                       \-                     1(50)        1(50)                     
  Genital ulcers           yes                    4(2.4)       34(20.3)     129(77.2)    p\>0.05
  no                       5(7.04)                11(15.49)    55(77.46)                 
  Ocular involvement       yes                    4(3.88)      32(31.06)    67(65.04)    p\>0.05
  no                       4(2.96)                30;(22.22)   101(78.81)                
  Deep venous thrombosis   yes                    4(9.75)      14(34.14)    23(56.09)    **p=0.01**
  no                       4(2.03)                48(24.36)    145(73.60)                
  Skin lesions             yes                    3(2.88)      31(29.80)    70(67.30)    p\>0.05
  no                       5(3.73)                31(23.13)    98(73.13)                 
  Response to colchicine   yes                    7(3.44)      37(18.22)    159(78.32)   p\>0.05
  no                       2(5.71)                9(25.71)     24(68.57)                 
  Papulopustule            yes                    4(4.16)      21(21.87)    71(73.95)    p\>0.05
  no                       5(3.52)                25(17.60)    112(78.87)                
  Erythema.nodusum         yes                    9(3.84)      43(18.37)    182(77.77)   p\>0.05
  no                       \-                     2(50)        2(50)                     

The results that are statistically significant are typed in bold. Wild type allele (P~1~) mutant type allele (P~2~).

###### *IL-4* allele frequencies according to the clinical characteristics in BD patients (n=238).

  **Clinical**             ***Il-4 alleles***                             
  ------------------------ -------------------- ------------ ------------ -------------
  Oral ulcers              yes                  63(13.34)    409(86.65)   p\>0.05
  no                       1(25)                3(75)                     
  Genital ulcers           yes                  42(12.57)    292(87.42)   p\>0.05
  no                       21(14.78)            121(85.21)                
  Ocular involvement       yes                  40(19.41)    166(80.58)   p\>0.05
  no                       38(14.07)            232(85.92)                
  Deep venous thrombosis   yes                  22(26.82)    60(73.17)    **p=0.008**
  no                       56(14.21)            338(85.78)                
  Skin lesions             yes                  37(17.78)    171(82.21)   p\>0.05
  no                       41(15.29)            227(84.70)                
  Response to colchicine   yes                  51(12.56)    355(87.43)   p\>0.05
  no                       13(18.57)            57(81.42)                 
  Papulopustule            yes                  29(15.10)    163(84.89)   p\>0.05
  no                       35(12.32)            249(87.67)                
  Erythema.nodusum         yes                  61(13.03)    407(86.96)   p\>0.05
  no                       2 (25)               6(75)                     

The results that are statistically significant are typed in bold. Wild type allele (P~1~) mutant type allele (P~2~).

###### Ocular involvement distribution according to deep venous thrombosis.

  **Clinical status (n,%)**   **Deep venous thrombosis (+)**   **Deep venous thrombosis (-)**   **Total (n,%)**   **χ^2^**   **P value**
  --------------------------- -------------------------------- -------------------------------- ----------------- ---------- -------------
  Ocular involvement (+)      92 (38.65%)                      11 (4.62%)                       103 (43.27%)                 
  Ocular involvement (-)      105 (38.65%)                     30 (12.60%)                      135 (56.72%)      5.459      **0.014**
  Total (n,%)                 197 (82.77%)                     41 (17.22%)                      238 (100%)                   

The results that are statistically significant are typed in bold

###### Distribution of IL-4 gene 70 bp VNTR genotype and allele frequencies according to clinical status.

  Clinical status                                     Genotype (n,%)   χ2          P value   Allele (n,%)   χ2          P value                      
  --------------------------------------------------- ---------------- ----------- --------- -------------- ----------- ---------- --------- ------- ----------
  Ocular involvement (+) Deep venous thrombosis (+)   6 (2.6)          4 (1.6)     1(0.5)    2.018          p=0.365     16 (3.4)   6 (1.2)   41.34   p\<0.001
  Ocular involvement (-) Deep venous thrombosis (-)   162 (68)         58 (24.4)   7 (2.9)   382 (80.2)     72 (15.2)                                

The results that are statistically significant are typed in bold. Homozygous wild type (P~1~P~1~) heterozygous mutant type (P~1~P~2~) homozygous mutation type (P~2~P~2~), Wild type allele (P~1~) mutant type allele (P~2~).

Discussion
==========

Behçet's disease is a multisystem vasculitis that can affect all sizes of blood vessels \[[@r18]-[@r22]\]. The disease was first defined by Hulusi Behçet, a Turkish professor of dermatology, in 1937 as a triad of recurrent aphthous stomatitis, genital aphthae, and relapsing uveitis \[[@r23]\]. BD has been reported worldwide but has a distinct geographic distribution with highest prevalences in countries along the ancient Silk Road route \[[@r23]\]. No specific pathological testing or technique is available for diagnosing the disease \[[@r23]\]. Ocular disease is usually bilateral and characteristically occurs within 2 to 3 years of disease onset. Ocular involvement is reported in 30% to 70% of patients with Behcet's disease. Uveitis involving the anterior and posterior uveal tracts is a significant cause of morbidity. Uveitis, posterior uveitis, and retinal vasculitis may cause visual loss in up to 25% of patients \[[@r24]\]. Although the etiology of BD is not yet known, immune dysregulation is critical factor in the pathogenesis \[[@r11]\]. Genetic factors that predispose individuals to BD play especially important roles in the development of the disease. Familial aggregation studies in patients with BD indicate a strong genetic background and a complex inheritance model \[[@r25]\]. There is a strong association with HLA-B51 and an increased incidence among close family members \[[@r26]-[@r28]\]. Venous thrombosis, a clinical finding of BD, is also a common multifactorial disease associated with a major public health burden. Vascular lesions, in particular subcutaneous thrombophlebitis and deep vein thrombosis, may also occur, being detected in 10% to 30% of patients with active disease \[[@r4],[@r5]\]. Vasculitis is the pathological lesion underlying most clinical manifestations of BD, including venous thrombosis. However, thrombophilia may also play an important role in the pathogenesis of the thrombotic manifestations observed in BD \[[@r6]\]. Retinal vein occlusion is associated with increased levels of vascular endothelial growth factor; antivascular endothelial growth factor therapy has been proposed as a promising strategy for retinal vein occlusion \[[@r29]\]. Genetic factors are known to contribute to the susceptibility to venous thrombosis, but how many genes are involved and their contribution to venous thrombosis risk remain obscure \[[@r30]\]. For BD, possible candidate antigens include vascular proteins, because the central histopathological finding in BD is a vasculitis, and environmental factors such as infectious agents, which may cause cross-reactivity to human antigens and result in immune activation \[[@r24]\].

Several previous studies have shown that cytokines play critical roles in the pathogenesis of BD, because cytokines mediate many of the effector and regulatory functions of immune and inflammatory responses \[[@r24]\]. Single nucleotide polymorphisms and a VNTR are the common polymorphisms found in the human genome and cause various disorders \[[@r31]\]. Ollier et al. wrote that variation in cytokine level has been correlated with disease susceptibility and progression \[[@r32]\]. This can be unraveled by investigating cytokine gene polymorphisms to determine whether a genetic basis for cytokine dysregulation is associated with disease. The genetic markers used most often in studies are either microsatellite repeat polymorphisms \[[@r33]\] or single nucleotide polymorphisms (SNPs) \[[@r34]\]. SNPs located in the intronic regions of genes can have no effect on either the level or quality of the protein produced, or, if positioned within an area influencing messenger ribonucleic acid splicing, lead to different splice variants. An *IL-4* gene polymorphism has been reported for its association with several diseases such as Graves disease \[[@r1]\], subacute sclerosing panencephalitis \[[@r2]\], rheumatoid arthritis \[[@r3]-[@r4]\], end-stage renal disease \[[@r5]\], idiopathic thrombocytopenic purpura \[[@r6]\], chronic polyarthritis \[[@r7]\], fibromyalgia \[8), malaria \[[@r9]\], transitional cell carcinoma of the urinary bladder \[[@r10]\], oral cancer \[[@r11]\], and gastric cancer \[[@r12],[@r35]\]. Several studies have investigated VNTR polymorphisms in different diseases \[[@r31],[@r35]-[@r39]\]. Based on these findings, we decided to investigate the effect of the 70 bp VNTR polymorphism on the third intron of the *IL-4* gene in Behçet's disease.

In this study, the distribution of the *IL-4* gene polymorphic genotypes was analyzed in patients with BD in a Turkish population to assess the possible role of these genotypes in the pathogenesis of BD. The present study indicates that the percentage of the *IL-4* polymorphism allele and the distribution of genotypes differed significantly between the patient group and the control group. When we examined *IL-4* genotype frequencies according to the clinical characteristics, we found a statistically significant association between the P2P2 genotype and deep venous thrombosis. Venous involvement is observed in 25% of patients with BD. Vascular lesions include arterial aneurysms, small-vessel vasculitis, and arterial and venous thrombosis. Venous thrombosis is more common than arterial thrombosis, deep vein thrombosis being the most frequent type of venous thrombosis \[[@r40]\]. The mechanism of the thrombosis in BD is not yet clearly understood. Venous thrombosis and inflammation are two closely related entities \[[@r41]\]. Previous studies have shown that levels of inflammatory substances known as cytokines are raised around the time of a thrombosis \[[@r42]-[@r44]\]. In addition, specific polymorphisms in cytokine genes are risk factors for venous thrombosis \[[@r42]-[@r44]\]. In this study, the deep venous thrombosis ratio was 29.8%. Men are more severely affected than women. In the present study, the male:female ratio was 1:1.1. The incidence rate of BD is higher in patients' family members than in the general population \[[@r4]\]. Therefore, genetic analysis is important to elucidate the pathogenic mechanism.

In previous studies, overexpression of proinflammatory cytokines from various cellular sources seemed to be responsible for the enhanced inflammatory reaction in BD, and this may be associated with the genetic susceptibility \[[@r40]\]. Oral et al. investigated *IL-4* and *IL-4Ra* gene polymorphisms, which are different from our polymorphic region, and found that the frequency of *IL-4* −1098 TG and 590 CT genotypes was higher in the patients with BD compared to healthy controls \[[@r11]\]. Analysis of allele frequencies showed that *IL-4* −1098 G and *IL-4* 590 T alleles were more common in patients with BD when compared to healthy controls.

They also reported that the *IL-4RA* gene polymorphism seems to confer pathergy test positivity in patients with BD, whereas none of the *IL-4* gene polymorphisms were associated with clinical findings and specific diagnostic tests for BD \[[@r11]\]. Kurata et al. reported that SNPs [rs9261365](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9261365) and [rs2074474](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2074474) were associated with BD independently of HLA-B51 and - A26 \[[@r45]\]. Akman et al. showed that the tumor necrosis factor-α --1031C allele is associated with susceptibility to BD in the Turkish population \[[@r46]\]. Kim et al. indicated that the interaction of specific [rs2275913](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2275913) in *IL-17A*, *IL-23R*, and [rs7574865](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7574865)/[rs11889341](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11889341)/[rs11685878](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11685878) in *STAT-4* SNPs modulate susceptibility to intestinal BD in the Korean population, suggesting that the IL-17/23 axis plays a significant role in disease pathogenesis \[[@r47]\]. Recently, genome-wide association studies revealed that variants [rs12119179](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12119179)/[rs1554286](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1554286) in *IL-10* and [rs1495965](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1495965) *IL-23R-IL-12RB2* are associated with BD \[[@r48],[@r49]\]. Other studies also identified a strong relationship between the polymorphisms of [rs17375018](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=17375018) *IL-23R* and *IL-17* and BD \[[@r50],[@r51]\]. Ozcimen et al. performed a study in Turkish patients with BD to determine the influence of single nucleotide polymorphisms in *IL-1A*, *IL-1B*, *IL-1R*, and *IL-1RA* on disease susceptibility \[[@r10]\]. The authors demonstrated that the *IL-1b* +3962 gene polymorphism seems to be associated with the presence of erythema nodosum in patients with BD. To the best of our knowledge, no reports have been published regarding the role of the *IL-4* 70 bp VNTR polymorphism in BD. Chen et al. reported that the plasma soluble endothelial protein C receptor (sEPCR) level was associated with the polymorphism of *EPCR* gene 6936A/G. The plasma sEPCR level in patients with deep venous thrombosis was higher than that in healthy control subjects \[[@r52]\]. Shahram et al. examined the *IL-2* (−330, +166), *IL-4* (−1098, −590, −33), *IL-10* (−1082, −819, −592), *IL-12* (−1188), *interferon-γ* (5644), transforming growth factor (TGF)-β (codon 10, 25), and *IL-4RA* (+1902) polymorphisms, and reported a significantly increased frequency of *IL-2* (−330) GG genotype (p\<0.001), *IL-4* (−33) CC genotype (p\<0.001), and *TGF-β* (codon 10) CC genotype (p=0.004). A significant decrease in the frequency of the *IL-4* (−33) TC genotype (p\<0.001) was reported in the patient group compared with healthy controls. The genotype CC of *TGF-β* at codon 10 was also significantly overrepresented in the patient group (p=0.004) \[[@r53]\]. Recent studies have suggested that the IL-23/IL-17 axis may be crucial to BD development. A study showed that the expression of IL-23p19 messenger ribonucleic acid, IL-23, IL-17, and interferon-c was markedly elevated in patients with BD with active uveitis \[[@r54]\]. In another study, nuclear factor κB (NF-κB) essential modulator (NEMO), heterozygous (1217A\>T, D406V) *NEMO* mutation is a cause of familial occurrence of Behcet's disease in female patients \[[@r55]\]. Ghioni et al. investigated potential associations between A-13G and G79A polymorphisms of the *protein Z* gene and venous thrombosis and other clinical manifestations in Italian patients with BD. However, no associations were found \[[@r56]\]. Cho et al. demonstrated that the heterogeneous nuclear ribonucleoprotein A2/B1 is a target protein of serum antiendothelial cell immunoglobulin A antibody in patients with BD. Reactivity of serum immunoglobulin A against human recombinant heterogeneous nuclear ribonucleoprotein A2/B1 was detected in 83.3% of patients with BD, whereas it was detected in 0% to 30% of healthy people and disease controls \[[@r57]\]. In a study performed in Turkey, the possible roles of methylenetetrahydrofolate reductase gene C677T, factor V gene G1691A (Leiden), and prothrombin gene G20210A polymorphisms in venous thrombogenesis were evaluated in patients with BD. No association was found among these three thrombogenetic mutations and patients with BD with thrombosis \[[@r39]\]. Several studies have shown that elevated levels of coagulation factors increase the thrombotic risk \[[@r58],[@r59]\]. Increased procoagulant levels might be acquired. Experimental studies in human volunteers injected with low-dose endotoxin provide credence to this possibility, as they showed increases in procoagulant protein levels in parallel with an inflammatory response \[[@r60]\]. Increased levels of inflammatory markers were also found in patients who had had venous thrombotic disease. Inflammation might increase procoagulant protein levels and thus increase the prothrombotic state of the blood \[[@r60]\]. In addition, inflammation may promote tissue factor expression of white blood cells and endothelial cells, thus providing a trigger that may lead to thrombotic disease \[[@r60]\].

In conclusion, our results suggest that possession of the P~1~ allele of the *IL-4* gene 70 bp VNTR polymorphism may constitute a risk for developing BD. Several studies have demonstrated that different genes mutations might play an important role in the etiology of BD. Due to limited research on the *IL-4* gene in BD, the present study makes an important contribution to the literature. Our study demonstrates that polymorphisms in the *IL-4* gene seem to be involved in the susceptibility to BD. Further work is required to confirm these findings in different study groups.
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